Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey - PubMed (original) (raw)
Multicenter Study
. 2007 Jul-Aug;23(6):535-42.
doi: 10.1097/AJP.0b013e318074c986.
Affiliations
- PMID: 17575495
- DOI: 10.1097/AJP.0b013e318074c986
Multicenter Study
Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey
Bjoern Hoffmann et al. Clin J Pain. 2007 Jul-Aug.
Abstract
Background: Fabry disease is a multisystemic life-threatening lysosomal storage disorder caused by deficiency of alpha-galactosidase A. Symptoms of the disease may occur in different organs including kidney, heart, and the nervous system.
Objectives: To evaluate the nature and prevalence of pain in a large cohort of patients with Fabry disease and to assess the effect of enzyme replacement therapy (ERT) with agalsidase alfa.
Methods: Retrospective analysis of the data of 752 patients with Fabry disease (393 females, 353 males) enrolled in the Fabry Outcome Survey, a multicentre database.
Results: The prevalence of pain in male patients was 81.4% (females 65.3%). Mean age at onset of pain was 14.8+/-1.0 year in males (females 19.8+/-1.4 y). Pain was most frequently reported in the hands (males 76%, females 60%) and feet (males 73%, females 52%), but often affected the whole body. Interference of pain with daily life was higher in females than in males, and was observed predominantly for general activities, mood, and normal work. Fifty-eight percent of the patients were on ERT with agalsidase alfa. At 24 and 36 months after commencement of ERT, pain severity classification shifted towards lower severity (P<0.05). Moreover, after 36 months, "average pain" and "pain now" were significantly reduced (P<0.05).
Conclusions: Pain is one of the most prevalent symptoms in Fabry disease with onset early in childhood. ERT with agalsidase alfa significantly reduces pain in this debilitating disorder.
Similar articles
- Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U. Ramaswami U. Drug Des Devel Ther. 2011 Mar 14;5:155-73. doi: 10.2147/DDDT.S11985. Drug Des Devel Ther. 2011. PMID: 21552486 Free PMC article. Review. - Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators. Hoffmann B, et al. J Med Genet. 2005 Mar;42(3):247-52. doi: 10.1136/jmg.2004.025791. J Med Genet. 2005. PMID: 15744039 Free PMC article. - Fabry disease: overall effects of agalsidase alfa treatment.
Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Beck M, et al. Eur J Clin Invest. 2004 Dec;34(12):838-44. doi: 10.1111/j.1365-2362.2004.01424.x. Eur J Clin Invest. 2004. PMID: 15606727 Clinical Trial. - Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H, Nagao M, Kino K. Sasa H, et al. Mol Genet Metab. 2019 Apr;126(4):448-459. doi: 10.1016/j.ymgme.2019.02.005. Epub 2019 Feb 20. Mol Genet Metab. 2019. PMID: 30803893 - Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM, Tylki-Szymańska A, Hilz MJ. Schaefer RM, et al. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Drugs. 2009. PMID: 19852524 Review.
Cited by
- Diet and Physical Activity in Fabry Disease: A Narrative Review.
Muscogiuri G, De Marco O, Di Lorenzo T, Amicone M, Capuano I, Riccio E, Iaccarino G, Bianco A, Di Risi T, Pisani A. Muscogiuri G, et al. Nutrients. 2024 Apr 4;16(7):1061. doi: 10.3390/nu16071061. Nutrients. 2024. PMID: 38613094 Free PMC article. Review. - Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.
Salviati A, Burlina AP, Borsini W. Salviati A, et al. Neurol Sci. 2010 Jun;31(3):299-306. doi: 10.1007/s10072-009-0211-y. Epub 2010 Mar 19. Neurol Sci. 2010. PMID: 20300794 Free PMC article. - Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U. Ramaswami U. Drug Des Devel Ther. 2011 Mar 14;5:155-73. doi: 10.2147/DDDT.S11985. Drug Des Devel Ther. 2011. PMID: 21552486 Free PMC article. Review. - Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.
Zedde M, Romani I, Scaravilli A, Cocozza S, Trojano L, Ragno M, Rifino N, Bersano A, Gerevini S, Pantoni L, Valzania F, Pascarella R. Zedde M, et al. Cells. 2024 Jun 29;13(13):1131. doi: 10.3390/cells13131131. Cells. 2024. PMID: 38994983 Free PMC article. Review. - Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.
Hoffmann B. Hoffmann B. Orphanet J Rare Dis. 2009 Oct 11;4:21. doi: 10.1186/1750-1172-4-21. Orphanet J Rare Dis. 2009. PMID: 19818152 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical